Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy

Annals of Hematology

Volumn 91, Issue 5, 2012, Pages 715-721

  Cornec, Divi ^a,b   Tempescul, Adrian ^b   Querellou, Solène ^a   Hutin, Pascal ^a   Pers, Jacques Olivier ^a,b   Jamin, Christophe ^a,b   Bendaoud, Boutahar ^a,b   Berthou, Christian ^a,b   Renaudineau, Yves ^a,b   Youinou, Pierre ^a,b  

^a Universite de Brest   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

C1qA; Fc gamma receptor; Low grade; Non Hodgkin's lymphoma; Rituximab; SUV max

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RITUXIMAB; ANTINEOPLASTIC AGENT; B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C1Q; DRUG DERIVATIVE; EPSILON HYDROXYNORLEUCINE; EPSILON-HYDROXYNORLEUCINE; FC RECEPTOR; FC RECEPTOR IIA; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NORLEUCINE; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; C1QA 276 GENE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FCYR GENE; FCYRIIA 131 GENE; FEMALE; GENE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; B CELL LYMPHOMA; BLOOD; CANCER GRADING; GENETICS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-CELL ACTIVATING FACTOR; COMPLEMENT C1Q; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM GRADING; NORLEUCINE; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RECEPTORS, IGG; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84861463268     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1369-y     Document Type: Article

References (38)

1. Maloney DG, Grillo-López AJ, White CA et al (1997) IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195 (Pubitemid 27392702)
2. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51
3. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P (2009) Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 76:458-463
4. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520-535 (Pubitemid 41295078)
5. Dall'Ozzo S, Tartas S, Paintaud G et al (2004) Rituximabdependent cytotoxicity by NK cells: influence of FcγRIIIa polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669 (Pubitemid 38856941)
6. Van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibodydependent cell cytotoxicity. Clin Cancer Res 12:4027-4035 (Pubitemid 44078090)
7. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant B cells. Cancer Immunol Immunother 48:673-683 (Pubitemid 30146462)
8. Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in Fc-gamma receptor IIIa gene. Blood 99:754-758 (Pubitemid 34525533)
9. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947 (Pubitemid 46606207)
10. Racila E, Link BK, Weng W et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697-6703
11. Berinstein NL, Grillo-López AJ, White CA et al (1998) Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001 (Pubitemid 28496709)
12. Davis TA, Grillo-López AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143
13. Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin's lymphoma: correlation with disease activity and patient outcome. Blood 104:2247-2253 (Pubitemid 39331819)
14. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465-475 (Pubitemid 37328738)
15. Pers J, Devauchelle V, Daridon C et al (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56:1464-1477 (Pubitemid 46764075)
16. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Staging Classification. Cancer Res 31:1860-1861
17. Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258-1265 (Pubitemid 39166497)
18. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586 (Pubitemid 350002966)
19. Cragg MS, Bayne MB, Tutt AL et al (2004) A new anti-Id antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104:2540-2542 (Pubitemid 39331858)
20. Saito Y, Miyagawa Y, Onda K et al (2008) BAFF inhibits CD20-mediated and BCR-mediated apoptosis in human B cells. Immunology 125:570-590
21. Le Pottier L, Bendaoud B, Renaudineau Y et al (2009) New ELISA for BAFF. Clin Chem 55:1843-1851
22. Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42-52 (Pubitemid 24005093)
23. Teeling JL, French RR, Cragg MS et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphoma. Blood 104:1793-1800 (Pubitemid 39202289)
24. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91:522-529
25. Le Dortz L, De Guibert S, Bayat S et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307-2314
26. Cazaentre T, Morschhauser F, Bermandel M et al (2010) Pretherapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:494-504
27. Hatjiharissi E, Xu L, Santos DD et al (2007) Increased NK cell expression of CD16, augmented binding and ADCC activity of rituximab among individuals expressing the FcγRIIIa-158V/V and V/F polymorphism. Blood 110:2561-2564 (Pubitemid 47523179)
28. Wu J, Edberg JC, Redecha PB et al (1997) A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059-1070 (Pubitemid 27386289)
29. Anolik JH, Campbell D, Felgar RE et al (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459 (Pubitemid 36278014)
30. Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B (2007) FcγRIIIa and FcγRIIa polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92:998-999 (Pubitemid 350144253)
31. Carlotti E, Palumbo GA, Oldani E et al (2007) FcγRIIIa and FcγRIIa polymorphisms do not predict clinical outcome of follicular NHL patients treated with sequential CHOP and rituximab. Haematologica 92:1127-1130 (Pubitemid 350144222)
32. Weng WK, Levy R (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 50:723-727
33. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in White patients, and for an FcγRIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26:5489-5491
34. Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587 (Pubitemid 36900094)
35. Nielsen CH, Fischer EM, Leslie RG (2000) The role of complement in the acquired immune response. Immunology 100:4-12 (Pubitemid 30242876)
36. Uchida J, Hamaguchi Y, Oliver JA et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-1669 (Pubitemid 38821999)
37. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821-830 (Pubitemid 38714746)
38. Novak AJ, Slager SL, Fredericksen ZS et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69:4217-4224